WXXWY WUXI BIOLGCS ADRWatchlist
WUXI BIOLGCS ADR News
Nomura Adjusts Wuxi Biologics' Price Target to HK$58.44 From HK$82.69, Keeps at Buy
06:14 AM EST, 12/05/2023 (MT Newswires) -- Nomura Adjusts Wuxi Biologics' Price Target to HK$58.44 From HK$82.69, Keeps at Buy Price (HKD): $30.35, Change: $-2.80, Percent Change: -8.45%
The CXO leader continues to collapse! Yaoming Biotech got on the “jumping plane” and plummeted by more than 30% in two days. What do the institutions think?
The decline is unstoppable.
Daimo: Reiterating Pharmacology Biotech (02269)'s “increase in holdings” rating, target price of HK$115.36
Dama believes that Pharmaceutical Biotech (02269) has the ability to overcome turbulent times and achieve growth higher than market expectations.
[Broker Focus] Bank International downgraded Pharmacology Biotech (02269) target price to HK$34 and downgraded to “neutral”
Jinwu Financial News | According to the Bank of China International Development Research Report, the growth rate of the core business of Pharmaceutical Biology (02269) declined, and the company lowered its revenue and profit guidelines for 2023-24. Revenue side: The company said that in 2023, excluding COVID-19, revenue growth is expected to be 36% (VS1H 2359.7%), but the overall revenue growth rate is expected to be only 10%, which is significantly lower than the previous growth rate of 30%. Mainly because: 1) Global investment and financing has entered a downward cycle; 2) the revenue of the three M-side projects was delayed until the end of 2024 to 2025 due to regulatory reasons; 3) the sharp decline in COVID-19 projects. Profit side: company expectations
Pharmaceutical Biotech (02269.HK) resumed trading this morning
On December 5, Gelonghui Biotech (02269.HK) announced that trading of the company's shares will resume at 9:00 a.m. today (5/12/2023). As a result, all structured products related to the company will also resume trading at the same time.
Pharmaceutical Biology (02269): Business operations and financial conditions maintained strong momentum, trading resumed on December 5
Pharmaceutical Biology (02269) announced that the company's shares will resume at 9:00 a.m. on December 5, 2023...
North-South Water | Nanshui Net bought Kweichow Moutai for 605 million yuan, and Beishui reduced stocks of Pharmaceutical Biology and Tencent
Track the latest developments in north-south funding
WuXi Biologics to Provide Business Update Soon; Trading in Shares Halted
WuXi Biologics (Cayman) (HKG:2269) said it would "convene a business update meeting today, [Dec. 4], at which it will conduct a presentation containing financial and other information regarding [its]
The 100 billion giant crashed! Triggered by PPT?
Gold, luxury goods, ice and fire are two heavens!
Pharmacovigilance disintegrates CXO, what is the market concerned about?
It was only in December that the full-year forecast was lowered. What kind of medicine does Yakumin Biotech sell in gourds?
Trending Industry Today: WUXI BIO Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
December 4th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending lower today with 1 constituents up, 7 constituents down and WUXI BIO lead
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process With a Breakthrough Productivity of ~6 G/L/day at Pilot Scale
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced today that it has accomplished end-to-end DS manufacturing at pilot scale utilizing WuXiUPTM, a proprietary ultra-high productivity continuous bioprocessing platform at its non-GMP pilot plant in Shanghai, China. Currently, this well configured bioprocess is being scaled up to GMP manufacturing and will be deployed across WuXi Biologics' global manufacturing sites in China, Ireland, U.S., Singapore.
Pharmaceutical Biology (02269) granted a total of 3,037,200 shares under the restricted share reward scheme
Pharmaceutical Biology (02269) issued an announcement. On November 21, 2023, the company's board of directors approved the grant...
WuXi Biologics Arm WuXi XDC Lists on HKEX
WuXi Biologics (Cayman) said subsidiary WuXi XDC Cayman (HKG:2268) began trading on the Hong Kong bourse earlier today, Nov. 17. The parent controls about 50.91% of the spin-off, according to a Friday
[IPO] Pharmacology Joint Stock Exchange (02268)'s initial listing of HK$26.95 was 30.83% higher than the prospectus
Jinwu Financial News | Pharmaceuticals Joint Alliance (02268), which was spun off from Pharmacology Biotech (02269), was listed at HK$26.95 on the first day of today, 30.83% higher than the offering price. Pre-market transactions amounted to 25.5395 million shares, with a turnover of 648 million yuan. No handling fees, 500 shares per lot, a book profit of HK$3,175. The Hong Kong public offering was oversubscribed by 48.96 times, and the first-hand winning rate was 13%. International placement was oversubscribed by about 18.6 times. After redistribution, Hong Kong's share of public sales increased to about 30%, while international placements accounted for about 70%. The listing price is 20.6 yuan, which falls within the scope of the prospectus price
WuXi XDC Cayman Raises HK$3.48 Billion From Hong Kong IPO, Prices at Top of Range
WuXi XDC Cayman (HKG:2268) priced its Hong Kong initial public offering Thursday to raise HK$3.48 billion in net proceeds from the offering. The antibody-drug conjugate research, development, and manu
Pharmacology Biotech issues 1.5 million shares under the adopted IPO pre-sale share option plan
Pharmacology Biotech (02269) announced that it will issue 1.5 million shares at an issue price of HK$1.29 per share on November 8, 2023, in accordance with the initial public pre-sale share option plan adopted on January 5, 2016. In addition, 93,500 shares were issued as a result of the exercise of the share options plan.
Pharmacology Biotech issues 500,000 shares in accordance with the adopted IPO pre-sale share option plan
Pharmaceutical Biology (02269) announced that it will issue 500,000 shares on November 7, 2023, in accordance with the initial public pre-sale share option plan adopted on January 5, 2016.
WuXi Biologics Receives AAA MSCI ESG Rating
SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA r
Pharmaceutical Biotech (02269) issues 500,000 shares under an adopted pre-IPO share option plan
Pharmaceutical Biology (02269) issued an announcement. It was adopted on November 7, 2023 according to January 5, 2016...